Currentsierra health and lifePolicy 2025T0569O

Transpupillary Thermotherapy Medical Policy

Defines UnitedHealthcare Commercial and Individual Exchange coverage position for transpupillary thermotherapy (TTT) including indications considered medically necessary (choroidal melanoma, retinoblastoma), and lists other indications considered unproven and not medically necessary; includes applicable procedure code references and policy administrative history.

Policy Summary

Payersierra health and life

PolicyTranspupillary Thermotherapy Medical Policy

Policy CodePolicy 2025T0569O

Change TypeTemplate Update (no clinical changes)

Effective DateJan 1, 2025

Next Review Date

Key ActionDocument clinical indication supporting use of TTT (choroidal melanoma or retinoblastoma) and rationale when used as adjunctive therapy; reference member specific benefit plan for coverage determination.

SourceLink

POLICY UPDATE CHANGES

Template Update; created shared policy version to support application to UnitedHealthcare West plan membership and archived previous policy versions 2024T0569N and MMG139.N.

2Medically Necessary Indications

multipleUnproven/Not Medically Necessary (examples)

2Reference unlisted CPT codes

Coverage Summary

Defines UnitedHealthcare Commercial and Individual Exchange coverage position for transpupillary thermotherapy (TTT). Coverage stance is mixed: TTT is considered medically necessary for select ocular tumors (specifically choroidal melanoma and retinoblastoma), and is unproven / not medically necessary for other indications (including choroidal neovascularization and age-related macular degeneration), due to insufficient evidence for benefit.

Policy Metadata

Policy number2025T0569O

PayerSierra Health and Life (applies UnitedHealthcare Commercial/Individual Exchange policy)

Effective date2025-01-01

Last review2025-01-01

StatusCURRENT

Medical Necessity Criteria

Medically Necessary Indications

Transpupillary thermotherapy is proven and medically necessary for treating the following:

ANY of the following

Choroidal melanomas
Retinoblastoma

Not Medically Necessary / Unproven Indications

Transpupillary thermotherapy is unproven and not medically necessary for treating all other indications due to insufficient evidence of efficacy. These include but are not limited to:

ANY of the following

Choroidal neovascularization
Macular degeneration
Other ocular conditions not listed as 'medically necessary' (e.g., peripheral retinal hemangioblastomas, Von Hippel-Lindau related RH, polypoidal choroidal vasculopathy, other CNV/AMD subtypes) due to limited/insufficient evidence

Provider Actions

Documentation Required

Confirm indication and documentation

Document the clinical indication supporting use of transpupillary thermotherapy (TTT) — specifically choroidal melanoma or retinoblastoma — and the clinical rationale when TTT is used adjunctively (for example, as a supplement to radiation or chemotherapy). Reference the member-specific benefit plan for coverage determination.

67299
92499

Prior Authorization

Benefit verification and prior authorization as required by plan

Verify member benefit coverage and obtain any required prior authorization according to the member-specific benefit plan before providing TTT. Check the member plan documents and applicable mandates as benefit coverage is determined by the member-specific plan.

Billing Rule

Use of unlisted codes

Report transpupillary thermotherapy using the appropriate unlisted posterior segment or ophthalmology service codes as applicable. Listing of a code in this policy is for reference only and does not imply coverage or reimbursement.

67299
92499

Background & Evidence

Transpupillary thermotherapy (TTT), also called diode laser hyperthermia, uses a diode laser to raise temperature within tumor tissue, producing heat-induced sclerosis of vascular channels and tumor regression. It has been studied primarily for ocular tumors such as choroidal melanoma and retinoblastoma, and has also been investigated for choroidal neovascularization, age-related macular degeneration (AMD), and other ocular conditions.

Evidence supports use of TTT for selected small choroidal melanomas and as adjunctive therapy in some settings: published series and randomized/controlled studies report tumor regression and variable recurrence rates, and guidelines (NCCN) note a role for TTT in small recurrences or when radiation/surgery are not feasible. For retinoblastoma, prospective and observational studies report good tumor control and eye-preservation rates when TTT is used as primary or adjunctive therapy in selected small tumors.

For other indications (for example CNV/AMD and various other ocular conditions), clinical trial data and systematic reviews are insufficient to demonstrate a vision benefit or consistent safety profile. Randomized trials show reduced anti-VEGF injection frequency with low-dose TTT but no improvement in visual acuity, and guideline bodies (NICE, AAO) have concluded evidence is inadequate or no longer recommend thermal laser for subfoveal CNV. Overall, evidence is insufficient to support TTT as medically necessary for these other indications.

Citation	Key finding
Mashayekhi et al. (2015)	Retrospective series (n=391) showed variable recurrence rates with 5- and 10-year recurrence higher in earlier cohort; recurrence correlated with number of high-risk tumor features; authors recommend alternative treatments for small melanomas with multiple risk factors.
NCCN (2023)	NCCN recommends TTT for small recurrences in patients who cannot undergo radiation or surgery and states TTT can be considered if initial radiation response is inadequate.
Söderberg et al. (2012)	Randomized trial in neovascular AMD: low-dose TTT plus ranibizumab reduced number of ranibizumab injections over 24 months but showed no significant difference in visual acuity or lesion measures; evidence insufficient to conclude vision benefit.

Definitions: Transpupillary thermotherapy (TTT) — diode laser hyperthermia applied through the pupil to raise temperature within tumor tissue, causing heat-induced sclerosis of vascular channels and tumor regression and resolution of subretinal fluid.